With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

GLP-1RAs were not associated with an increased risk for thyroid cancer relative to DPP-4 inhibitor use among an international cohort.

SGLT2 inhibitors and GLP-1RAs yielded lower risks for COPD exacerbation than DPP-4 inhibitors among patients with type 2 diabetes.

The primary outcome of the study was the first hematologic cancer diagnosis. One analysis compared GLP-1RA recipients to metformin recipients, and another compared the former to those taking insulin.

The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes ...

Ozempic and its ilk may do a lot of things, but raising the risk of suicide doesn’t appear to be one of them. Research out ...

The rates of depression were similar for the GLP-1RA group and sodium-glucose cotransporter-2 inhibitor (SGLT2i) group. However, compared to participants taking dipeptidyl peptidase-4 inhibitors ...

Studies in patients with type 2 diabetes are needed to further assess and allow comparison of several GLP-1RA agents' impact on steady-state pharmacokinetics and pharmacodynamics of concomitant ...

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

Earlier animal trials had shown how the glucagon-like peptide 1 receptor agonist (GLP-1RA) semaglutide (Wegovy, Ozempic) drastically changed the way rats and mice sought out alcohol 'rewards ...

The rates of depression were similar for the GLP-1RA group and sodium-glucose cotransporter-2 inhibitor (SGLT2i) group. However, compared to participants taking dipeptidyl peptidase-4 inhibitors ...